1.Alternative Name：TNFSF7,CD27LG；CD27 Ligand; CD27-L; CD27LCD27 ligand; CD27LG; CD70 molecule; CD70; Ki-24 antigen; surface antigen CD70; TNFSF7; TNFSF7CD70 antigen; tumor necrosis factor (ligand) superfamily, member 7; Tumor necrosis factor ligand superfamily member 7
2.Target：CD70
3.Source：Human CD70 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence：Ser52-Pro193
5.Protein structure:：P32970hFC
6.Molecular Characterization:The protein has a calculated MW of 73kDa.The non-reducing (N-R) heterodimer protein migrates as 140-160 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>90%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 90%.

13.ELISA

When Recombinant Human CD70/ hFC Protein is immobilized at 5μg/mL (100 μL/well), the concentration of Anti-Human CD70 (Cusatuzumab) that produces 50% of the optimal binding response is approximately 20 ng/ml.

14.SPR

Recombinant Human CD70/ hFC Protein（Cat.No.B22045006）captured on Protein A chip , can bind Recombinant Human CD27/ His Protein（Cat.No.B22045002） with a KD constant of 4.95E-07M, determined in a SPR assay .

15.Note:For Research Use Only.